Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase 3 Study to Determine the Efficacy of TG-C in Subjects With Kellgren and Lawrence Grade (KLG) 2 or 3 Osteoarthritis of the Knee
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 15 Apr 2024
Price :
$35
*
At a glance
- Drugs Tonogenchoncel-L (Primary)
- Indications Osteoarthritis
- Focus Registrational; Therapeutic Use
- Sponsors Kolon TissueGene
- 23 Dec 2022 Planned End Date changed from 30 Jun 2025 to 30 Aug 2025.
- 23 Dec 2022 Planned primary completion date changed from 30 Jun 2024 to 30 Aug 2024.
- 28 Dec 2021 According to a Kolon TissueGene media release, company has resumed patient dosing.